Central Neuropathic Pain Clinical Trial
Official title:
An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo
[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian participants with central neuropathic pain (central neuropathic pain after spinal cord injury) receiving mirogabalin versus placebo. [Open Extension Phase] The objective is to assess the long-term safety and efficacy of mirogabalin in participants with central neuropathic pain (central neuropathic pain after spinal cord injury, central post stroke pain, and central neuropathic pain in Parkinson's disease). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT06071949 -
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
|
Phase 3 | |
Recruiting |
NCT06072001 -
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
|
Phase 3 | |
Recruiting |
NCT05357066 -
Nitrous Oxide as Treatment for Fibromyalgia
|
Phase 2 | |
Not yet recruiting |
NCT06422117 -
Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China
|
Phase 3 | |
Not yet recruiting |
NCT04665492 -
EEG Predictors of Neuropathic Pain in SCI
|
||
Completed |
NCT00313820 -
Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
|
Phase 4 | |
Completed |
NCT02218203 -
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
|
Phase 2 |